Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(14):1028-1029; doi:10.1093/jnci/95.14.1028
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Correction (v95,p1255)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by DuBois, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DuBois, R. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 14, 1028-1029, July 16, 2003
© 2003 Oxford University Press

EDITORIAL

Leukotriene A4 Signaling, Inflammation, and Cancer

Raymond N. DuBois

Affiliation of author: Departments of Medicine, Cell-Developmental Biology, and Cancer Biology, The Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.

Correspondence to: Raymond N. DuBois, M.D., Ph.D., Department of Medicine/Gastroenterology, Hepatology, and Nutrition, MCN C-2104, Vanderbilt University Medical Center, 1161 21st Ave. South, Nashville, TN 37232-2279 (e-mail: raymond.dubois@vanderbilt.edu).

The first 10% of the full text of this article appears below.

Chen et al. report in this issue of the Journal that leukotriene A4 hydrolase (LTA4H) was overexpressed in 10 rat esophageal adenocarcinomas compared with matched normal tissue samples (1). They also report that LTA4H was expressed in infiltrating inflammatory cells and in the columnar cells in human esophageal adenocarcinomas. Bestatin, an LTA4H inhibitor, reduced the incidence of esophageal adenocarcinomas by approximately 30% in a rat esophageal carcinoma model. On the basis of these findings, the authors conclude . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. H.M. Reid, A. Protheroe, G. Attard, N. Hayward, L. Vidal, J. Spicer, H. M. Shaw, E. A. Bone, J. Carter, L. Hooftman, et al.
A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors
Clin. Cancer Res., August 1, 2009; 15(15): 4978 - 4985.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
H. Lu, W. Ouyang, and C. Huang
Inflammation, a Key Event in Cancer Development
Mol. Cancer Res., April 1, 2006; 4(4): 221 - 233.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Hoque, S. M. Lippman, T.-T. Wu, Y. Xu, Z. D. Liang, S. Swisher, H. Zhang, L. Cao, J. A. Ajani, and X.-c. Xu
Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention
Carcinogenesis, April 1, 2005; 26(4): 785 - 791.
[Abstract] [Full Text] [PDF]